United Therapeutics (UTHR) | Stock Overview & Key Data
United Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $609.35 on May 6, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
United Therapeutics
UTHR
|
25.11B Large-cap | -6.64% | -7.08% | 5.10% | 13.90% | 8.72% | 74.63% | 156.34% | 216.46% | 378.74% | 788.07% | 2,079.33% |
|
Zoetis
ZTS
|
49.75B Large-cap | -4.46% | -31.75% | -39.76% | -38.95% | -38.30% | -53.93% | -54.80% | -55.66% | 62.09% | 150.53% | 150.53% |
|
Haleon Plc - ADR
HLN
|
42.40B Large-cap | -5.84% | -5.84% | -19.96% | -10.03% | -13.00% | -20.18% | 9.16% | 22.27% | 22.27% | 22.27% | 22.27% |
|
Viatris
VTRS
|
16.99B Large-cap | -3.51% | 3.22% | -0.06% | 46.50% | 25.92% | 84.98% | 74.28% | 5.65% | -63.48% | -28.81% | -22.24% |
|
Intra-Cellular
ITCI
|
14.05B Large-cap | N/A | N/A | N/A | N/A | N/A | 92.68% | 104.13% | 700.67% | 449.92% | 632.61% | 632.61% |
| 14.00B Large-cap | -4.77% | -15.39% | -11.30% | 87.60% | 12.71% | 3.55% | 3,950.85% | 8,435.71% | 8,435.71% | 8,435.71% | 8,435.71% |
Ownership & Short Interest
Calculate Your United Therapeutics Investment Returns
Long-Term Investment Performance Analysis
United Therapeutics stock price in May 2016 was $116.31, A $1,000.00 lump sum investment in United Therapeutics made 10 years ago would be worth approximately $4,643.19 today, representing a exceptional return of 364.32%. This translates to an annualized return (CAGR) of 16.58%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is UTHR's 52-week high and low?
- In the last 52 weeks, United Therapeutics reached a high of $609.35 (on May 6, 2026) and a low of $272.12 (on July 31, 2025).
- What is the market cap and P/E ratio for UTHR?
- Curious about United Therapeutics's size and valuation? Its market capitalization stands at 25.11B. When it comes to valuation, the P/E ratio (trailing twelve months) is 20.60, and the forward P/E (looking ahead) is 16.87.
- Does UTHR pay dividends? If so, what's the yield?
- As for dividends, United Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are United Therapeutics's main competitors or similar companies to consider before investing?
When looking at United Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS49.75B Healthcare Drug Manufacturers - Specialty & Generic -53.93% -54.80% Haleon Plc - ADR
HLN42.40B Healthcare Drug Manufacturers - Specialty & Generic -20.18% 9.16% Viatris
VTRS16.99B Healthcare Drug Manufacturers - Specialty & Generic 84.98% 74.28% Intra-Cellular
ITCI14.05B Healthcare Drug Manufacturers - Specialty & Generic 92.68% 104.13% Regencell Bioscience
RGC14.00B Healthcare Drug Manufacturers - Specialty & Generic 3.55% 3,950.85% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for United Therapeutics Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of United Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 19.72%, the Debt to Equity ratio from the most recent quarter is 0.53, and its Gross Profit Margin stands at 86.91%.
- What is the recent revenue and earnings growth for UTHR?
- Looking at United Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $3B. Compared to the same quarter last year (YoY), quarterly revenue grew by 7.40%, and quarterly earnings saw a YoY growth of 20.90%.
- How much of UTHR stock is held by insiders and institutions?
- Wondering who owns United Therapeutics stock? Company insiders (like executives and directors) hold about 1.94% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 97.78%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.